|
Biomarker Science
MedQIA is a leader in bringing imaging biomarker science to clinical trials. Our biomarker R&D program is a multidisciplinary, collaborative effort encompassing imaging physics, computer vision, pattern classification, biostatistics, and radiological sciences.
In the setting of multicenter clinical trials, consistency and reproducibility of measurements are key elements. MedQIA achieves this through standardization of image acquisition parameters, image quality control metrics, and computer-aided image segmentation and analysis tools. MedQIA imaging biomarkers are developed using state of the art machine learning techniques applied to large research databases that correlate quantitative imaging features with biological changes and treatment outcomes.
Cutting-edge computer vision technology is used to extract quantitative biomarkers from images with greater reproducibility than subjective visual assessments. They provide early objective evidence of therapeutic efficacy for accelerated drug development. Additionally, predictive biomarkers can select patients who are most likely to benefit from targeted therapies, resulting in reduced clinical trial sizes and improved patient outcomes. The future of imaging biomarkers is in early, non-invasive decision making - "who should be treated, with what, and when."
|
